Genocea Biosciences (GNCA) Earning Somewhat Negative Press Coverage, Accern Reports
News coverage about Genocea Biosciences (NASDAQ:GNCA) has been trending somewhat negative recently, according to Accern Sentiment Analysis. The research firm ranks the sentiment of press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Genocea Biosciences earned a media sentiment score of -0.05 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 42.8984454208235 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Genocea Biosciences (NASDAQ:GNCA) traded down $0.06 during trading hours on Tuesday, hitting $1.06. 631,500 shares of the stock were exchanged, compared to its average volume of 455,000. The company has a market cap of $30.14, a P/E ratio of -0.49 and a beta of 1.94. The company has a quick ratio of 1.55, a current ratio of 1.55 and a debt-to-equity ratio of 2.51. Genocea Biosciences has a one year low of $1.01 and a one year high of $7.29.
Genocea Biosciences (NASDAQ:GNCA) last announced its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.08). During the same period last year, the business posted ($0.45) EPS. equities research analysts predict that Genocea Biosciences will post -1.91 earnings per share for the current fiscal year.
GNCA has been the subject of a number of analyst reports. Zacks Investment Research raised shares of Genocea Biosciences from a “hold” rating to a “buy” rating and set a $1.75 price objective for the company in a report on Monday, October 16th. Cowen reaffirmed a “buy” rating and set a $10.00 price objective on shares of Genocea Biosciences in a report on Tuesday, September 26th. Stifel Nicolaus downgraded shares of Genocea Biosciences from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $15.00 to $2.50 in a report on Monday, September 25th. Needham & Company LLC downgraded shares of Genocea Biosciences from a “buy” rating to a “hold” rating in a report on Tuesday, September 26th. Finally, Piper Jaffray Companies reaffirmed an “overweight” rating and set a $5.00 price objective on shares of Genocea Biosciences in a report on Thursday, November 2nd. One analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the stock. Genocea Biosciences has a consensus rating of “Hold” and an average target price of $6.25.
About Genocea Biosciences
Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.